Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of$ 0.96. This compares to a loss of $1.7 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +17.71%. A quarter ago, it was expected that this company would post a loss of$ 0.99 per share when it actually produced a loss of $1.01, delivering a surprise of -2.02%. While Sage Therapeutics has outperformed ...